摘要
目的探究异丙托溴铵联合布地奈德可改善COPD急性加重期患者肺功能和全身免疫炎性反应指数的影响。方法选取我院2020年11月至2022年11月COPD急性加重期患者共100例,均行基础治疗。随机分为对照组与观察组两组,对照组50例,实施异丙托溴铵;观察组50例,联合应用异丙托溴铵溶液和吸入用布地奈德混悬液。比较两组患者治疗前后肺功能指标,IL-6(白介素6)、TNF-α(肿瘤坏死因子),全身免疫炎性反应指数(SIRI)变化。比较两组患者治疗后症状好转时间和临床疗效评估。统计两组患者不良反应发生情况。结果观察组患者治疗后临床有效率明显高于对照组患者(P<0.05)。观察组患者治疗后肺功能指标改善情况显著优于对照组患者(P<0.05)。观察组患者治疗后肺IL-6,TNF-α和SIRI与对照组患者相比明显降低(P<0.05)。对照组患者治疗过程中咳嗽缓解时间,气促消失时间,喘息消失时间和肺部体征消失时间明显长于观察组(P<0.05)。两组患者不良反应统计无差异(P>0.05)。结论布地奈德联合异丙托溴铵治疗COPD急性加重期患者可有效减轻患者炎症反应,改善患者肺功能,提升患者疗效,并且不会增加患者不良反应的发生。
Objective Ipratropium bromide and budesonide were used together to study their potential impact on lung function and systemic immune-inflammatory index in patients experiencing acute exacerbations of chronic obstructive pulmonary disease(COPD).Methods In our hospital,100 patients diagnosed with acute COPD exacerbation received standard treatment between November 2020 and November 2022.These patients were divided into two groups-a control group and an observation group,each consisting of 50 individuals.The control group received ipratropium bromide,while the observation group received a combination of ipratropium bromide solution and inhaled budesonide suspension.Before and after treatment,the lung function indicators,as well as levels of IL-6,TNF-α,and SIRI,were compared between the two groups.Additionally,the time taken for symptom improvement and clinical efficacy evaluation post-treatment were compared.The incidence of adverse reactions in both groups was also subjected to statistical analysis.Results The observation group showed a significantly higher clinical efficacy rate post-treatment compared to the control group(P<0.05).Improvement in lung function indicators post-treatment was notably better in the observation group than in the control group(P<0.05).Following treatment,the observation group exhibited significantly lower levels of IL-6,TNF-α,and SIRI compared to the control group(P<0.05).The duration for relief of cough,disappearance of shortness of breath,disappearance of wheezing,and resolution of pulmonary signs during treatment was notably shorter in the observation group compared to the control group(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The pairing of budesonide and ipratropium bromide has been shown to effectively decrease the inflammatory response,enhance lung function,improve therapeutic outcomes for individuals experiencing acute exacerbation of COPD,and does not result in a higher risk of adverse reactions.
作者
席冰洁
龚晓露
许欣
XI Bing-jie;GONG Xiao-lu;XU Xin(The First People's Hospital of Shangqiu City,Shangqiu 476000,Henan Province,China)
出处
《罕少疾病杂志》
2024年第5期42-44,共3页
Journal of Rare and Uncommon Diseases
基金
河南省医学科技攻关计划(LHGJ20191349)。
